GLP-1 receptor agonists — the blockbuster class behind drugs like Ozempic and Wegovy — don't appear to change how often patients with diabetic macular edema (DME) need anti-VEGF eye injections, according to a large retrospective study presented at the American Academy of Ophthalmology (AAO) annual meeting. Analyzing nearly 10,000 matched patient pairs from the AAO's IRIS Registry over 36 months, researchers found no meaningful shift in injection frequency, visual acuity, or retinal thickness after GLP-1 initiation. The conclusion: DME management should continue to be guided by ocular disease activity, not GLP-1 use.

But GLP-1s and the eye aren't a simple story. A separate study using Epic Cosmos data initially showed GLP-1 users had higher AMD odds — until researchers adjusted for diabetes, hypertension, and hyperlipidemia, at which point the drugs appeared protective against AMD. Meanwhile, two studies flagged a concerning trend: GLP-1 users develop anterior ischemic optic neuropathy (AION) at a younger age and experience second-eye involvement significantly sooner than non-users.

Key Takeaways:

• GLP-1 use does not reduce anti-VEGF treatment burden in existing DME — ocular disease activity should remain the primary treatment guide
• GLP-1s may be protective against AMD after accounting for confounders like diabetes and hypertension — but more rigorous studies are needed
• Clinicians should take a thorough GLP-1 medication history in patients presenting with AION, especially when counseling after a first-eye event

Why it matters: As GLP-1 drugs become increasingly widespread, understanding their ophthalmic effects is critical. These findings offer reassurance for DME patients but signal a need for heightened vigilance around AION — a potentially blinding condition.